ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Corporate structure

23 entities across 19 jurisdictions, 1 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-12 — see the exhibit.

Financial health

Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.

Six-year record

Ownership flow

16 institutions tracked — 8 added, 7 reduced, 1 opened a new position. Index money added 671,213 shares while active managers cut 2,983,209.

NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.

From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.

Other pharmaceutical preparations companies

ALNYLAM PHARMACEUTICALS, INC. files under SIC 2834 — all 50 pharmaceutical preparations companies compared on assets and F-score.

Dealer positioning — end of day

Where dealer gamma sat in ALNY’s option chain after the close on 2026-09-01, aggregated from the full chain. This is a once-a-day snapshot, not a live read — 357 contracts.

Net gamma (per 1% move)

$4.6M

Gamma flip

250

Call wall

260

Put wall

200

Spot at capture

240.69

Computed from the listed option chain by my own aggregation, once, after the close — it describes where positioning sat that evening and does not update through the next session. The version that rebuilds per strike while the market is open is the intraday gamma product. Not investment advice.

Questions about ALNYLAM PHARMACEUTICALS, INC.

How many subsidiaries does ALNYLAM PHARMACEUTICALS, INC. file with the SEC?

23, listed in its most recent exhibit 21. They are incorporated across 19 jurisdictions, led by Delaware, United Kingdom, Massachusetts. 1 of them sit in offshore financial centres. That exhibit is filed with the company's annual report and is the company's own list, not an estimate.

Is ALNYLAM PHARMACEUTICALS, INC. financially healthy?

ALNYLAM PHARMACEUTICALS, INC. scores 5 out of 7 on the Piotroski F-score. Only 7 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.

Who are the largest institutional holders of ALNYLAM PHARMACEUTICALS, INC.?

Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are FMR LLC (adding), Capital World Investors (adding), BlackRock, Inc. (adding). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.